Edition:
United Kingdom

People: Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

4.65USD
9:00pm BST
Change (% chg)

$-0.12 (-2.52%)
Prev Close
$4.77
Open
$4.86
Day's High
$4.90
Day's Low
$4.57
Volume
273,126
Avg. Vol
422,196
52-wk High
$5.02
52-wk Low
$1.29

Fisherman, Jason 

Dr. Jason S. Fisherman, M.D., serves as Independent Director of Achillion Pharmaceuticals, Inc., since March 2000. Since 2007, Dr. Fisherman is a Partner in Synthesis Ventures, an early stage venture firm he co-founded in 2007. From January 2016, to September 2016, Dr. Fisherman was the President and Chief Executive Officer of C4 Therapeutics, a biotechnology company building a platform for targeted protein-degrading drugs. From 1994 to 2007, Dr. Fisherman was an investor in life science and healthcare companies at Advent International, a global private equity firm, becoming a Managing Director in 2002. Prior to Advent, Dr. Fisherman served for three years as Senior Director of Medical Research at Enzon Pharmaceuticals, leading development of drugs for cancer and orphan diseases. He previously managed the clinical development of a number of oncology drugs at the National Cancer Institute. Dr. Fisherman has served on numerous public and private biotechnology and healthcare company boards. Dr. Fisherman received a B.A. from Yale University, his M.D. from the University of Pennsylvania and a M.B.A. from the Wharton School of the University of Pennsylvania

Basic Compensation

Total Annual Compensation, USD 72,675
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 87,037
Fiscal Year Total, USD 159,712

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --